← All drugs
Drug · FAERS side-effect profile with label screen

Iodide I-131 side effects: what 165 FDA adverse event reports show

Sodium Iodide I-131 · 5 reaction terms · 42 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Radioactive therapeutic agent

FDA label, Indications wording of the closest related product

Label matched

Sodium Iodide I-131 (Sodium Iodide I-131)

closest FDA label found for this product string; brand list suppressed because the label is a related product, not an exact match

Who reports

165 reports · 88% serious · 13 with death outcome · 66% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Sodium Iodide I-131 Solution is indicated for the treatment of hyperthyroidism and selected cases of thyroid carcinoma. Sodium Iodide I-131 is a radioactive therapeutic agent indicated for the treatment of hyperthyroidism and selected cases of carcinoma of the thyroid.

FDA label, Indications and Usage

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 4 strongest signals

Labeled adverse reaction 1Labeled (related wording) 1Likely indication confounding 1Not in label — unassessed 1
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 1 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Hyperthyroidism870.3
35.8–138.3ROR 73.8 · χ² 480 / p 1e-106
60.6 EB05 32.9 · IC025 +2.6
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
serious PRR 43.0no trial data cached
Hypothyroidism1767.9
43.3–106.5ROR 75.6 · χ² 1,055 / p 9e-232
63.3 EB05 41.8 · IC025 +3.7
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 48.6no trial data cached
Premature baby729.5
14.3–60.8ROR 30.7 · χ² 165 / p 4e-38
27.0 EB05 13.3 · IC025 +2.0
3/3 methods agree
Not in label — unassessedserious PRR 19.5no trial data cached

Trial evidence (ClinicalTrials.gov)

Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Hypothyroidism1767.9
43.3–106.5ROR 75.6 · χ² 1,055 / p 9e-232
63.3 EB05 41.8 · IC025 +3.7
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 48.6no trial data cached
Hyperthyroidism870.3
35.8–138.3ROR 73.8 · χ² 480 / p 1e-106
60.6 EB05 32.9 · IC025 +2.6
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
serious PRR 43.0no trial data cached
Premature baby729.5
14.3–60.8ROR 30.7 · χ² 165 / p 4e-38
27.0 EB05 13.3 · IC025 +2.0
3/3 methods agree
Not in label — unassessedserious PRR 19.5no trial data cached
Blood thyroid stimulating hormone increased455.1
20.9–145.0ROR 56.4 · χ² 162 / p 2e-37
43.2 EB05 17.0 · IC025 +1.2
3/3 methods agree
Lab value / disease markerserious n=3no trial data cached

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Iodide I-131?

In FDA FAERS, the most frequently co-reported reaction terms for Iodide I-131 are hypothyroidism, hyperthyroidism, premature baby, abortion spontaneous, blood thyroid stimulating hormone increased. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Iodide I-131 have an FDA boxed warning?

No. The FDA label retrieved for Iodide I-131 has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Iodide I-131 causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.